Crossject Expands Reach with New Commercialization Agreement

The French pharmaceutical group, Crossject, has inked a new commercialization deal, expanding its reach to cover a population of 170 million. The identity of the partner remains undisclosed. This development marks a significant stride for Crossject, promising milestone payments up to 1 million euros, contingent on the grant of marketing authorizations in the pertinent countries. In addition to these payments, Crossject will also get a cut of the gross margin generated.

An Equitable Agreement

Under the agreement's terms, Crossject must shoulder the costs linked with regulatory development. However, it will retain ownership of any marketing authorizations obtained. On the other hand, the partner will cover commercial costs. This agreement adds to a series of commercial contracts and firm orders that Crossject has recently secured.

Previous Commercial Agreements

This new agreement follows a firm order from the United States' Biomedical Advanced Research and Development Authority (BARDA) and another commercialization contract for Zepizure in Australia and New Zealand. The latter is managed by AF Pharmaceuticals and caters to nearly 30 million people. These agreements, coupled with the BARDA order, emphasize Crossject's progress towards the ultimate commercialization of their product, Zepizure.

Anticipating Zepizure's Launch

The company is gearing up for the launch of Zepizure in these territories, pending the necessary marketing authorizations. The commercialization agreement in Northern Europe for Zepizure covers Germany, the UK, Denmark, Sweden, Finland, and Norway. Crossject is liable for regulatory development costs, with the undisclosed partner financing some of the development and filing-related expenses. This agreement, along with the BARDA order in the US and the commercialization agreement for Australia and New Zealand, underscores the advancement in Zepizure's future commercialization.